A Systematic Review and Meta-Analysis of Pelvic Drain Insertion After Robot-Assisted Radical Prostatectomy.

Journal: Journal of endourology
Published Date:

Abstract

To perform a systematic review and meta-analysis and to assess the clinical benefit of prophylactic pelvic drain (PD) placement after robot-assisted laparoscopic prostatectomy (RALP) with pelvic lymph node dissection (PLND) in patients with localized prostate cancer. An electronic search of databases, including Scopus, Medline, and EMbase, was conducted for articles that considered postoperative outcomes with PD placement and without PD (no drain) placement after RALP. The primary outcome was rate of symptomatic lymphocele (requiring intervention) and secondary outcomes were complications as described by the Clavien-Dindo classification system. Quality assessment was performed using the Modified Cochrane Risk of Bias Tool for Quality Assessment. Six relevant articles comprising 1783 patients (PD = 1253; ND = 530) were included. Use of PD conferred no difference in symptomatic lymphocoele rate (risk difference 0.01; 95% confidence interval [CI] -0.007 to 0.027), with an overall incidence of 2.2% (95% CI 0.013-0.032). No difference in low-grade (I-II; risk difference 0.035, 95% CI -0.065 to 0.148) or high-grade (III-V; risk difference -0.003, 95% CI -0.05 to 0.044) complications was observed between PD and ND groups. Low-grade (I-II) complications were 11.8% (95% CI 0-0.42) and 7.3% (95% CI 0-0.26), with similar rates of high-grade (III-V) complications, being 4.1% (95% CI 0.008-0.084) and 4.3% (95% CI 0.007-0.067) for PD and ND groups, respectively. PD insertion after RALP with extended PLND did not confer significant benefits in prevention of symptomatic lymphocoele or postoperative complications. Based on these results, PD insertion may be safely omitted in uncomplicated cases after consideration of clinical factors.

Authors

  • Wenjie Zhong
    Nepean Urology Research Group, Nepean Hospital, Kingswood, Australia.
  • Matthew J Roberts
    Faculty of Medicine, The University of Queensland, Brisbane, Australia.
  • Jeremy Saad
    Nepean Urology Research Group, Nepean Hospital, Kingswood, Australia.
  • Isaac A Thangasamy
    Nepean Urology Research Group, Nepean Hospital, Kingswood, Australia.
  • Ranjan Arianayagam
    Nepean Urology Research Group, Nepean Hospital, Kingswood, Australia.
  • Niranjan J Sathianathen
    Division of Cancer Surgery, Peter MacCallum Cancer Centre, University of Melbourne, Australia.
  • Rasha Gendy
    Nepean Urology Research Group, Nepean Hospital, Kingswood, Australia.
  • Ahmed Goolam
    Nepean Urology Research Group, Nepean Hospital, Kingswood, Australia.
  • Mohamed Khadra
    Nepean Urology Research Group, Nepean Hospital, Penrith New South Wales, Australia.
  • Mohan Arianayagam
    Nepean Urology Research Group, Nepean Hospital, Penrith New South Wales, Australia.
  • Celi Varol
    Nepean Urology Research Group, Nepean Hospital, Penrith New South Wales, Australia.
  • Raymond Ko
    Nepean Urology Research Group, Nepean Hospital, Penrith New South Wales, Australia.
  • Bertram Canagasingham
    Nepean Urology Research Group, Nepean Hospital, Penrith New South Wales, Australia.
  • Richard Ferguson
    Nepean Urology Research Group, Nepean Hospital, Penrith New South Wales, Australia.
  • Matthew Winter
    Nepean Urology Research Group, Nepean Hospital, Penrith New South Wales, Australia.